AR128717A1 - Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 - Google Patents
Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2Info
- Publication number
- AR128717A1 AR128717A1 ARP230100560A ARP230100560A AR128717A1 AR 128717 A1 AR128717 A1 AR 128717A1 AR P230100560 A ARP230100560 A AR P230100560A AR P230100560 A ARP230100560 A AR P230100560A AR 128717 A1 AR128717 A1 AR 128717A1
- Authority
- AR
- Argentina
- Prior art keywords
- cdk2
- solid form
- compound
- formula
- salt
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 9
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 title 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 7
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 abstract 5
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000001816 cooling Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente solicitud proporciona formas sólidas y sales de un compuesto de fórmula (1), composiciones farmacéuticas de estos, métodos para tratar una enfermedad o un trastorno asociados con CDK2 mediante su uso, y procesos para preparar el compuesto de fórmula (1) y las formas sólidas y las sales. Reivindicación 1: Una forma sólida de un compuesto de fórmula (1), que es la Forma I, que es cristalina. Reivindicación 43: Una composición farmacéutica que comprende la forma sólida de cualquiera de las reivindicaciones 1 - 17 o la sal de cualquiera de las reivindicaciones 18 - 42 y un portador farmacéuticamente aceptable. Reivindicación 44: Un método para inhibir CDK2, que comprende poner en contacto la CDK2 con la forma sólida de cualquiera de las reivindicaciones 1 - 9 o la sal de cualquiera de las reivindicaciones 18 - 42. Reivindicación 45: Un método para inhibir CDK2 en un paciente, que comprende administrar al paciente la forma sólida de cualquiera de las reivindicaciones 1 - 9 o la sal de cualquiera de las reivindicaciones 18 - 42. Reivindicación 46: Un método para tratar una enfermedad o un trastorno asociado con CDK2 en un paciente, que comprende administrar al paciente una cantidad terapéuticamente eficaz de la forma sólida de cualquiera de las reivindicaciones 1 - 9 o la sal de cualquiera de las reivindicaciones 18 - 42. Reivindicación 53: Un proceso para preparar una forma sólida de cualquiera de las reivindicaciones 1 - 9, que comprende enfriar una solución del compuesto de fórmula (1) en un componente disolvente que comprende etanol y agua. Reivindicación 69: Una sal de hemisuccinato de un compuesto de fórmula (1a).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263317308P | 2022-03-07 | 2022-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR128717A1 true AR128717A1 (es) | 2024-06-05 |
Family
ID=85724788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP230100560A AR128717A1 (es) | 2022-03-07 | 2023-03-07 | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230279004A1 (es) |
AR (1) | AR128717A1 (es) |
TW (1) | TW202342023A (es) |
WO (1) | WO2023172921A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
PL202623B1 (pl) | 2000-06-28 | 2009-07-31 | Smithkline Beecham Plc | Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna |
CN100523216C (zh) | 2001-03-02 | 2009-08-05 | 匹兹堡大学 | Pcr方法 |
US6812341B1 (en) | 2001-05-11 | 2004-11-02 | Ambion, Inc. | High efficiency mRNA isolation methods and compositions |
MXPA04002243A (es) | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
ATE335490T1 (de) | 2001-10-30 | 2006-09-15 | Novartis Pharma Gmbh | Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung |
CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
KR20060111716A (ko) | 2002-01-22 | 2006-10-27 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온 |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
US7252976B2 (en) | 2002-08-28 | 2007-08-07 | Board Of Regents The University Of Texas System | Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
CN101213297B (zh) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
CN101945867A (zh) | 2007-12-19 | 2011-01-12 | 安姆根有限公司 | 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
MX349463B (es) | 2008-09-26 | 2017-07-31 | Univ Emory | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
EP3567042B1 (en) | 2010-10-25 | 2021-07-07 | G1 Therapeutics, Inc. | Cdk inhibitors |
DK2937349T3 (en) | 2011-03-23 | 2017-02-20 | Amgen Inc | CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 |
ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
PE20191532A1 (es) | 2016-12-22 | 2019-10-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
JP7303108B2 (ja) | 2016-12-22 | 2023-07-04 | インサイト・コーポレイション | 免疫調節剤としての二環式複素芳香環化合物 |
LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
WO2021072232A1 (en) * | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
-
2023
- 2023-03-07 AR ARP230100560A patent/AR128717A1/es unknown
- 2023-03-07 TW TW112108351A patent/TW202342023A/zh unknown
- 2023-03-07 US US18/179,838 patent/US20230279004A1/en active Pending
- 2023-03-07 WO PCT/US2023/063875 patent/WO2023172921A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW202342023A (zh) | 2023-11-01 |
WO2023172921A1 (en) | 2023-09-14 |
US20230279004A1 (en) | 2023-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR128717A1 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
UY39029A (es) | Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2 | |
PE20231438A1 (es) | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo | |
AR116753A1 (es) | Proceso de preparación de un derivado de pirazolsulfonilamida | |
UY28280A1 (es) | 2- hidroxi - 3- diaminoalcanos de benzamida | |
CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
KR20190020170A (ko) | 통풍 또는 고뇨산혈증과 관련된 증상의 치료 또는 예방을 위한 화합물, 조성물 및 방법 | |
PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
CO6251286A2 (es) | Sales amino del acido [4, 6-bis(dimetilamino)-2-(4-(4-trifluorometil)benzamido)bencil)pirimidin-5-il]acetico, composiciones farmaceuticas de las mismas y sus usos para el tratamiento de enfermedades mediadas por crth-2 | |
AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
CO2021014210A2 (es) | Compuestos de pirrol | |
AR127501A1 (es) | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos | |
CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
MX2022009967A (es) | Compuestos para el tratamiento de la infeccion por coronavirus. | |
AR124036A1 (es) | Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición | |
DOP2021000254A (es) | Compuestos de pirrolidina | |
ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
AR126215A1 (es) | Proceso novedoso | |
AR127561A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
ECSP21093897A (es) | Compuestos y métodos de uso de los mismos como agentes antibacterianos | |
BR112023024037A2 (pt) | Sal farmaceuticamente aceitável de derivado de pirazoloheteroarila, formas cristalinas, composição farmacêutica, usos dos mesmos e métodos para preparar as referidas formas cristalinas e composição farmacêutica | |
AR126835A1 (es) | Análogos deuterados y derivados de 4-bromo-2,5-dimetoxifenetilamina y usos de estos | |
CO2023015293A2 (es) | Forma cristalina del compuesto derivado tricíclico, método para preparar la misma y composición farmacéutica que comprende la misma |